Pheon Therapeutics ^Companies

Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that focuses on developing next-generation ADCs for a wide range of hard-to-treat cancers. Their lead program is a first-in-class ADC targeting a novel tumor marker that is highly expressed in solid tumors across various cancer types. Founded in 2022 and based in London, England, Pheon Therapeutics aims to provide innovative solutions for difficult-to-treat cancers through their cutting-edge ADC technology.